echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Dolutegravir's first imitation: Qilu takes the lead in launching clinical trials

    Dolutegravir's first imitation: Qilu takes the lead in launching clinical trials

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 6, Qilu Pharmaceutical's "Dolutegravir Sodium Tablets" started the BE trial


    From: Insight database (http://db.


    Dolutegravir (DTG) is an anti-AIDS drug developed by GlaxoSmithKline/ViiV, which is an integrase inhibitor


    According to the Insight database, there are currently 3 compound preparations approved for marketing of dolutegravir in addition to single drugs worldwide


    Global sales of dolutegravir-related drugs

    Dolutegravir sales trend over the years

    From: Insight database (http://db.


    At present, apart from Qilu, no other companies have applied for the start of clinical trials of dolutegravir generic drugs


    Qilu Pharmaceuticals has recently not only increased its efforts in bio-innovative drugs, but has continued to be the king of traditional generic drugs, and is advancing extremely fast


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.